Immunohistochemical Analyses of Mammalian Target of Rapamycin (mTOR) Expression in Pituitary Neuroendocrine Tumors (PitNETs): mTOR as a Therapeutic Target for Functional PitNETs-Reference-Cited by-同舟云学术

Immunohistochemical Analyses of Mammalian Target of Rapamycin (mTOR) Expression in Pituitary Neuroendocrine Tumors (PitNETs): mTOR as a Therapeutic Target for Functional PitNETs

Published:2023-12-28 Issue:6 Volume:56 Page:121-126
ISSN:0044-5991
Container-title:ACTA HISTOCHEMICA ET CYTOCHEMICA
language:en
Short-container-title:Acta Histochem. Cytochem

Author:

Nakazato Ichiro¹,Shiomi Takayuki²,Oyama Kenichi³,Matsuno Akira³,Inomoto Chie⁴,Yoshiyuki Osamura R.⁵

Affiliation:

1. Basic Medical Sciences, International University of Health and Welfare, Graduate School of Medicine

2. Department of Pathology, International University of Health and Welfare Narita Hospital

3. Department of Neurosurgery, International University of Health and Welfare Mita Hospital

4. Department of Diagnostic Pathology, Tokai University Hospital

5. Department of Diagnostic Pathology, Nippon Koukan Hospital

Publisher

Japan Society of Histochemistry & Cytochemistry

Subject

Cell Biology,Histology,Physiology,Biochemistry,Pathology and Forensic Medicine

Link

https://www.jstage.jst.go.jp/article/ahc/56/6/56_23-00039/_pdf

Reference19 articles.

1. 1 Asa, S. L. and Ezzat, S. (2009) The pathogenesis of pituitary tumors. Annu. Rev. Pathol. 4; 97–126.

2. 2 Cerovac, V., Monteserin-Garcia, J., Rubinfeld, H., Buchfelder, M., Losa, M., Florio, T., et al. (2010) The somatostatin analogue octreotide confers sensitivity to rapamycin treatment on pituitary tumor cells. Cancer. Res. 70; 666–674.

3. 3 Chen, R., Duan, J., Li, L., Ma, Q., Sun, Q., Ma, J., et al. (2017) mTOR promotes pituitary tumor development through activation of PTTG1. Oncogene. 36; 979–988.

4. 4 Dworakowska, D., Wlodek, E., Leontiou, C. A., Igreja, S., Cakir, M., Teng, M., et al. (2009) Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors. Endocr. Relat. Cancer. 16; 1329–1338.

5. 5 Faivre, S., Kroemer, G. and Raymond, E. (2006) Current development of mTOR inhibitors as anticancer agents. Nat. Rev. Drug. Discov. 5; 671–688.